Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000321 | 0.93 | GAA (0.50) | GAATSHRALOX15HSD17B10BIRC2 | |
| SCHEMBL11952852 | 0.93 | GAA (0.47) | GAATSHRALOX15HSD17B10BIRC2 | |
| SCHEMBL11952846 | 0.86 | GAA (0.61) | GAATSHRALOX15HSD17B10CYP1A2 | |
| SCHEMBL361321 | 0.86 | GAA (0.56) | GAATSHRALOX15HSD17B10BIRC2 | |
| SCHEMBL8185716 | 0.84 | PHGDH (0.47) | HSD17B10PHGDHCYP1A2TDP1MAPT | |
| SCHEMBL12569136 | 0.82 | GAA (0.76) | GAATSHRALOX15HSD17B10BIRC2 | |
| SCHEMBL6963350 | 0.82 | GAA (0.63) | GAATSHRALOX15HSD17B10BIRC2 | |
| SCHEMBL209616 | 0.82 | GAA (0.63) | GAATSHRALOX15HSD17B10BIRC2 | |
| SCHEMBL30098873 | 0.81 | GAA (0.80) | GAATSHRALOX15HSD17B10BIRC2 | |
| SCHEMBL254801 | 0.81 | GAA (0.67) | GAATSHRALOX15HSD17B10BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| WO-2021227440-A1 | A CLASS OF ARYL GLUCOSIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海喆邺生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| WO-2014082889-A1 | NOVEL IMIDAZOLINES AS DUAL INHIBITORS OF MDM2 AND MDMX | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148443-A1 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX | HOFFMANN-LA ROCHE INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8513239-B2 | Chiral cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2203437-B1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| EP-2325180-A1 | Chiral CIS-imidazolines | F. Hoffmann-La Roche AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| EP-2203437-A1 | CHIRAL CIS-IMIDAZOLINES | F. Hoffmann-Roche AG (CH) | 2010-07-07 | — | — | EP | disclosed |
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN-LA ROCHE, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2009047161-A1 | CHIRAL CIS-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SLC5A1, SLC5A2, SLC10A1 | GAA 344/4885TSHR 3176/4885ALOX15 845/4885 |
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | FOXM1, CCNE1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | GAA 3283/4885TSHR 1143/4885ALOX15 4722/4885 |
| US-20140148443-A1 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX | MDM2, MDM4, TP53 | GAA 3521/4885TSHR 2816/4885ALOX15 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.